AKT1 and colorectal cancer: Other studies have found that ANL overcomes the multidrug resistance of colorectal cancer cells to cytotoxic drugs by inhibiting the PI3K/AKT pathway16, suggesting that after treatment, patients are resistant to multiple cytotoxic drugs, and the combined use of ANL may be beneficial again.